Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells

European Journal of Cancer

Volumn 51, Issue 16, 2015, Pages 2480-2489

  Tokunaga, Yoshimasa ^a   Liu, Dage ^a   Nakano, Jun ^a   Zhang, Xia ^a   Nii, Kazuhito ^a   Go, Tetsuhiko ^a   Huang, Cheng Long ^b   Yokomise, Hiroyasu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b Kitano Hospital   (Japan)

Author keywords

Adenovirus; Chemotherapeutic sensitivity; Gemcitabine; Gene therapy; RRM1; shRNA

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; CASPASE 7; GEMCITABINE; MESSENGER RNA; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE LARGE SUBUNIT M1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; RRM1 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; VIRAL GENE THERAPY; ADENOVIRIDAE; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; LUNG NEOPLASMS; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; RNAI THERAPEUTICS; TIME; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MALE; MICE, NUDE; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNAI THERAPEUTICS; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943662289     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.05.013     Document Type: Article

References (34)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 1 2014 9 29
2. N. Thatcher, A. Chang, P. Parikh, and et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 9496 2005 1527 1537
3. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, and et al. Erlotinib in previously treated non-small-cell lung cancer New Engl J Med 353 2 2005 123 132
4. V.A. Miller, V. Hirsh, J. Cadranel, and et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncol 13 5 2012 528 538
5. D.M. Jackman, V.A. Miller, L.A. Cioffredi, and et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Clin Cancer Res 15 16 2009 5267 5273
6. A. Wong, R.A. Soo, W.P. Yong, and F. Innocenti Clinical pharmacology and pharmacogenetics of gemcitabine Drug Metab Rev 41 2 2009 77 88
7. S.J. Elledge, Z. Zhou, and J.B. Allen Ribonucleotide reductase: regulation, regulation, regulation Trends Biochem Sci 17 3 1992 119 123
8. P. Nordlund, and P. Reichard Ribonucleotide reductases Annu Rev Biochem 75 2006 681 706
9. V. Heinemann, Y.Z. Xu, S. Chubb, and et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine Mol Pharmacol 38 4 1990 567 572
10. J.D. Davidson, L. Ma, M. Flagella, S. Geeganage, L.M. Gelbert, and C.A. Slapak An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines Cancer Res 64 11 2004 3761 3766
11. L.P. Jordheim, O. Guittet, M. Lepoivre, C.M. Galmarini, and C. Dumontet Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells Mol Cancer Ther 4 8 2005 1268 1276
12. A.M. Bergman, P.P. Eijk, V.W. Ruiz van Haperen, and et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant Cancer Res 65 20 2005 9510 9516
13. Y. Nakano, S. Tanno, K. Koizumi, and et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells Br J Cancer 96 3 2007 457 463
14. G. Reid, N.C. Wallant, R. Patel, and et al. Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase J RNAi Gene Silencing 5 1 2009 321 330
15. Q. Wang, X. Liu, J. Zhou, and et al. Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer PLoS ONE 8 7 2013 e70191
16. R. Rosell, E. Felip, M. Taron, and et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery Clin Cancer Res 10 12 Pt 2 2004 4215s 4219s
17. R. Rosell, K.D. Danenberg, V. Alberola, and et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin Cancer Res 10 4 2004 1318 1325
18. P. Ceppi, M. Volante, S. Novello, and et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine Ann Oncol 17 12 2006 1818 1825
19. J.J. Lee, C.H. Maeng, S.K. Baek, and et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC) Lung Cancer 70 2 2010 205 210
20. H. Yokomise, D. Liu, S. Chang, and et al. Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery Anticancer Res 33 3 2013 1107 1115
21. L. Scherer, and J.J. Rossi RNAi applications in mammalian cells Biotechniques 36 4 2004 557 561
22. C. Huang, M. Li, C. Chen, and Q. Yao Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications Expert Opin Ther Targets 12 5 2008 637 645
23. T.R. Brummelkamp, R. Bernards, and R. Agami A system for stable expression of short interfering RNAs in mammalian cells Science 296 5567 2002 550 553
24. D.D. Rao, J.S. Vorhies, N. Senzer, and J. Nemunaitis siRNA vs. shRNA: similarities and differences Adv Drug Deliv Rev 61 9 2009 746 759
25. W.F. Anderson Human gene therapy Nature 392 6679 Suppl 1998 25 30
26. R. Vile Cancer gene therapy - new approaches to tumour cell killing J Gene Med 2 2 2000 141 143
27. Y. Kanegae, M. Makimura, and I. Saito A simple and efficient method for purification of infectious recombinant adenovirus Jpn J Med Sci Biol 47 3 1994 157 166
28. P. Wonganan, W.G. Chung, S. Zhu, K. Kiguchi, J. Digiovanni, and Z. Cui Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells Cancer Biol Ther 13 10 2012 908 914
29. L. Taricani, F. Shanahan, M.C. Malinao, M. Beaumont, and D. Parry A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells PLoS ONE 9 11 2014 e111714
30. S. Pereira, P.A. Fernandes, and M.J. Ramos Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine J Comput Chem 25 10 2004 1286 1294
31. W.B. Parker, S.C. Shaddix, C.H. Chang, and et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate Cancer Res 51 9 1991 2386 2394
32. R. Rosell, G. Scagliotti, K.D. Danenberg, and et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer Oncogene 22 23 2003 3548 3553
33. W. Gong, X. Zhang, J. Wu, and et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis Lung Cancer 75 3 2012 374 380
34. G. Bepler, I. Kusmartseva, S. Sharma, and et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer J Clin Oncol 24 29 2006 4731 4737